2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.03 Anti-PD-1 Therapy Plus Denosumab in Advanced Non-Small Cell Lung Cancer with Bone Metastases: A Single-Centre, Retrospective Study in China

EP.11A.03 Anti-PD-1 Therapy Plus Denosumab in Advanced Non-Small Cell Lung Cancer with Bone Metastases: A Single-Centre, Retrospective Study in China

Back to course

Pdf Summary

This retrospective study conducted by Jianya Zhou and colleagues at Zhejiang University School of Medicine in China examined the efficacy of combining anti-PD-1 therapy with denosumab in treating advanced non-small cell lung cancer (NSCLC) patients with bone metastases. The analysis included 66 patients from March 2021 to June 2022, with outcomes such as overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety being evaluated.<br /><br />The study found that the objective response rate was 36.4%, with partial responses observed in 24 patients. At a median follow-up of 20.1 months, the median OS was 21.5 months and the median PFS was 7.7 months. Interestingly, the OS was better among patients who received more than six doses of denosumab, at 23.3 months compared to 15.3 months for those who received less. Similarly, PFS was longer in patients treated with more than six doses (8.1 vs. 6.3 months).<br /><br />Safety analysis indicated that 46.8% of patients experienced adverse events (AEs), with 19.4% encountering Grade 3 AEs. The most common AEs included decreased white blood cell count, pyrexia, anemia, and fatigue. No cases of osteonecrosis of the jaw were reported.<br /><br />The results suggest that combining immunotherapy with denosumab can improve clinical outcomes in NSCLC patients with bone metastases, highlighting the importance of treatment adherence. The study also introduced a novel method for quantitatively assessing tumor response in bone metastases using ROI ratios, which could aid in monitoring bone lesions.<br /><br />The authors conclude that this combination therapy demonstrates potential benefits and warrants further investigation, emphasizing the need for persistence in denosumab treatment to optimize survival outcomes.

Asset Subtitle

Jianya Zhou

Meta Tag

Speaker Jianya Zhou

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

retrospective study

anti-PD-1 therapy

denosumab

NSCLC

bone metastases

overall survival

progression-free survival

adverse events

tumor response

treatment adherence